Try our beta test site
123 studies found for:    (lymphoma [CONDITION] OR CLL [CONDITION]) AND "CCI-779" [TREATMENT]
Show Display Options
Rank Status Study
1 Completed
Has Results
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
Condition: Lymphoma
Interventions: Drug: Temsirolimus (CCI-779);   Drug: Investigator's choice
2 Unknown  Temsirolimus in Recurrent Primary Central Nervous System (CNS) Lymphoma
Condition: Recurrent or Refractory Primary CNS Lymphoma
Intervention: Drug: temsirolimus
3 Completed Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: everolimus;   Genetic: molecular response by PCR
4 Completed Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma
Condition: CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma
Interventions: Drug: AEB071;   Drug: Everolimus
5 Completed Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma
Condition: B-cell Lymphoma Refractory
Interventions: Drug: Inotuzumab Ozogamicin;   Drug: Temsirolimus
6 Completed Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
Condition: Non-Hodgkins Lymphoma
Interventions: Drug: Velcade;   Drug: Temsirolimus
7 Withdrawn Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL)
Condition: Cutaneous T-cell Lymphoma (CTCL)
Intervention: Drug: Sirolimus 0.1% Ointment
8 Completed
Has Results
CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Condition: Recurrent Mantle Cell Lymphoma
Interventions: Biological: rituximab;   Drug: temsirolimus
9 Recruiting Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
Condition: Non-Hodgkin's Lymphoma (NHL)
Intervention: Drug: temsirolimus
10 Unknown  Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma
Condition: Hodgkin's Lymphoma
Intervention: Drug: Temsirolimus
11 Completed
Has Results
Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma
Condition: Lymphoma
Interventions: Drug: Panobinostat;   Drug: Everolimus
12 Active, not recruiting Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma
Conditions: Follicular Lymphoma;   Mantle Cell Lymphoma
Intervention: Drug: Temsirolimus, Rituximab, Bendamustin
13 Completed
Has Results
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
Condition: Hodgkin Lymphoma
Intervention: Drug: Everolimus (RAD001)
14 Terminated CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Conditions: Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia
Interventions: Drug: temsirolimus;   Other: laboratory biomarker analysis
15 Completed A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Everolmus
16 Terminated
Has Results
Everolimus in Treating Cutaneous T-cell Lymphoma
Condition: Cutaneous T-Cell Lymphoma
Intervention: Drug: Everolimus
17 Completed Safety and Efficacy of RAD001 in Patients With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy.
Condition: Lymphoma, Mantle- Cell
Intervention: Drug: RAD001
18 Completed CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma
Condition: Recurrent Mantle Cell Lymphoma
Intervention: Drug: temsirolimus
19 Completed Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: RAD001;   Drug: Placebo
20 Active, not recruiting STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma
Condition: Diffuse Large B-Cell Lymphoma
Intervention: Drug: Rituximab, Temsirolimus, DHAP, intravenous

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.